The Path to Personalized Medicine.¶
Hamburg, M. A., & Collins, F. S. (2010). The Path to Personalized Medicine. New England Journal of Medicine, 363(4), 301-304.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Primes¶
- Distributional Effects
- In drug development, average dose-response hides responder/non-responder distinctions, and personalized medicine is the explicit move to act on the distribution rather than the average.
This sourceArgues personalized medicine acts on responder/non-responder heterogeneity rather than the average dose-response.
Supported in partVerified against the work's full text
Hamburg and Collins describe personalized medicine as targeting drugs to genetically defined patient subgroups and noting variable response, but never discuss average dose-response.
“salvaging of abandoned or failed drugs by identifying subgroups of patients likely to benefit from them”
- In drug development, average dose-response hides responder/non-responder distinctions, and personalized medicine is the explicit move to act on the distribution rather than the average.
Verification¶
Does it exist? Confirmed. This work's DOI resolves to a registered record, which fixes its identity. That is all it fixes.
Does it back the claim? Read against the text for 1 of 1 citation: 1 supported in part. Each verdict is shown under its citation below, with what in the work backs the sentence.
Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.
See how references were verified.
Registry ID ref:e637a20ab0af · see in the full table